Use of an Integrated Therapy With Prolonged Exposure to Treat PTSD and Comorbid Alcohol Dependence in an Iraq Veteran
Publication: American Journal of Psychiatry
[Case Study]
The patient was a 25-year-old single Caucasian Marine veteran with a history of three deployments in Iraq (21 months total), where he engaged in reconnaissance duties and served as a gunner. While on a mission, the patient witnessed the shooting of a close comrade by sniper fire. He assisted in providing medical care to his wounded comrade, who died in the patient's arms while en route to a hospital. After returning to the United States, the patient experienced daily intrusive memories and nightmares about the shooting. He avoided crowds and social situations, engaged in heavy alcohol use, and grew distant from his family and friends. He reported severe hyperarousal in crowded stores and became physically violent in situations where he felt provoked.
Treatment and Progress
The following measures were used for diagnostic assessment and to monitor progress: the Mini International Neuropsychiatric Interview (1) to assess psychiatric diagnoses; the Clinician-Administered PTSD Scale (CAPS) (2) to assess PTSD diagnosis and symptoms; the PTSD Checklist–Military Version (3) for weekly monitoring of PTSD severity; the Beck Depression Inventory, 2nd edition (BDI) (4), for weekly assessment of depressive symptoms; the timeline follow-back method (5) to monitor self-report daily use of substances; urine drug screens to assess illicit drug use; and breath alcohol tests to assess recent alcohol use. Throughout treatment and follow-up, an independent assessor administered the Mini International Neuropsychiatric Interview, the CAPS, and the timeline follow-back.
At baseline, the patient scored in the clinical range for PTSD (CAPS score=71; PTSD Checklist score=53), exhibited mild depression (BDI score=17), had a positive breath alcohol test, and consumed approximately 12.5 beers per day on 50/60 days (83.3%) prior to baseline.
The patient was treated with an integrated, exposure-based PTSD/substance use disorder psychotherapy called “COPE” (concurrent treatment of PTSD and substance use disorders using prolonged exposure). COPE consists of 12 individual 90-minute sessions that integrate relapse prevention for substance use and prolonged exposure for PTSD. Each session consisted of a substance use and a PTSD treatment component. In the first 30 minutes of each session, the clinician evaluated the patient's alcohol consumption since the last session, assessed high-risk situations encountered, and discussed techniques for managing cravings. In session 1, the patient's identified goal was to reduce alcohol consumption from 12.5 to 5.0 standard drinks per day, 3 days per week. Sessions 2 and 3 focused on learning skills to manage cravings and thoughts about using alcohol. The patient's alcohol use frequency and severity diminished markedly by session 3 (Figure 1) and remained low through the 3-month follow-up. All urine drug screens and breath alcohol tests after baseline were negative.
FIGURE 1. Alcohol Use Severity, PTSD Symptoms, and Depressive Symptoms During Treatment and Follow-Upa
a In vivo exposures began in session 3 and imaginal exposures in session 4.
During the remaining 60 minutes of each session, PTSD was addressed. In sessions 1–3, education on fear and avoidance, the rationale for concurrent treatment, breathing retraining (a relaxation exercise), and the rationale for in vivo and imaginal exposures were provided. In session 3, the clinician and patient constructed an in vivo hierarchy comprising safe situations that the patient had been avoiding. The patient selected two in vivo exposures to complete each week, starting with situations that provoked a moderate amount of subjective discomfort (e.g., going to a movie theater, calling a friend), gradually moving up to situations associated with greater discomfort (e.g., going to a crowded festival). As a result of engaging in the in vivo exposures, the patient was able to visit family, develop new friendships, engage in social activities, and begin dating again. The use of in vivo exposures in patients with co-occurring substance use disorders requires careful assessment. Situations that increase exposure to substances or have a high probability of inducing craving are not included in the hierarchy. For example, going to a bar where the patient previously drank alcohol would not be a safe in vivo exposure assignment. Patients must be instructed not to use any substances before, during, or immediately after engaging in exposures. Alcohol use in this context would represent a “safety behavior” that would dilute the exposure's therapeutic effects.
Imaginal exposures (sessions 4–11) consisted of repeatedly recounting the memory of the shooting, in the present tense, with eyes closed, for 30–45 minutes. This was followed by approximately 10 minutes of processing and of discussing the thoughts and feelings that came to mind during the imaginal exposure. Starting in session 8, “hot spots” (the most distressing parts of the trauma memory) were repeated. Finally, in session 11, the entire memory was revisited. The patient listened to a recording of the imaginal exposure each day and reported that this daily exercise helped him to do the imaginal exposures in session. Processing focused primarily on the patient's feelings of guilt in two areas: 1) his belief that he should have been able to prevent his comrade's death by locating the enemy sniper ahead of time and 2) his belief that he should have been the one who was killed, not his comrade. Through a series of questions (e.g., “What did you do differently than what you were trained to do?” and “How would it have made it any better had you been the one killed?”), the patient was able to realize that he did everything he was trained to do as a Marine, yet neither he nor any of his other comrades were able to prevent the shooting. He realized, too, that his own death would not have resulted in an improved outcome. As a result of these cognitive shifts, the patient was better able to accept both outcomes as unfair “circumstances of war.” The reaction of the patient's senior commanding officer following the death of his comrade was also an important part of processing. The patient felt angry and vulnerable when he saw his commanding officer “break down” outside the hospital.
Several challenges occurred during treatment. For example, during session 1 the patient related a desire to reduce his use of alcohol rather than to abstain from it entirely. Although abstinence may be an ideal goal, the therapist thought the most effective approach would be to meet the patient “where he was at” by using a nonconfrontational approach. By session 4, the patient had surpassed his goal and was abstaining from alcohol the majority of each week. Another challenge involved two separate instances during the patient's in vivo exposure assignments (i.e., social activities) where he felt provoked and became physically violent with other men. Anger was discussed as a common symptom of PTSD, and skills for managing anger were reviewed and role-played in session to help prevent future violent episodes.
In the final session, the patient's progress toward accomplishing the treatment goals established during the first session was reviewed, areas for continued focus were discussed, and an emergency plan to help prevent relapse of alcohol use was generated. In session 12, the patient scored in the nonclinical range for PTSD and depression, with a CAPS score of 42, a PTSD Checklist score of 23, and a BDI score of 3, all of which were reliable changes as defined by Jacobson's Reliable Change Index (6) and based on standard deviations and scale reliabilities reported for veterans with PTSD (7). Treatment gains were maintained at the 3-month follow-up visit, as evidenced by a CAPS score of 17, a BDI score of 4, and a PTSD Checklist score of 26. The patient reported using alcohol only a few times since the end of treatment; his average number of drinks consumed per day during the 60 days prior to the 3-month follow-up visit was 0.35. At 6-month follow-up, the patient demonstrated continued symptom improvement, with a CAPS score of 4, a BDI score of 3, and a PTSD Checklist score of 23. He reported no alcohol use during the 60 days prior to the 6-month follow-up visit.
Discussion
Exposure to war-zone stress confers significant risk for a broad range of detrimental mental health effects, in particular posttraumatic stress disorder (PTSD) and substance use disorders. Among veterans of the recent conflicts in Afghanistan and Iraq, approximately 15%–17% suffer from PTSD (8–11) and up to 24% demonstrate alcohol misuse (12, 13). Veterans of these conflicts who have PTSD are more than twice as likely as those without PTSD to have an alcohol use disorder (10).
Despite the relative frequency of PTSD and comorbid substance use disorders, empirical evidence for guiding treatment is sparse. Historically, the standard of care has been the sequential model, in which the substance use disorder is treated first and trauma work deferred until the patient achieves a period of sustained abstinence (e.g., 6 months). This deferment is based primarily on the concern that trauma work will lead to substance use exacerbation. Contrary to these early, largely anecdotal concerns, a burgeoning literature examining integrated models, in which both disorders are addressed simultaneously, documents significant improvement in substance use severity, PTSD symptoms, and global functioning outcomes (14, 15). Compelling evidence is also provided by studies investigating the temporal course of improvement in symptoms. These studies show that patients who achieve improvement in PTSD symptoms are significantly more likely to show subsequent improvement in substance use, but the reciprocal relationship is less robust, with only minimal evidence that improvement in substance use yields improvement in PTSD symptoms (16, 17). Taken together, the accumulating data highlight the critical need to address PTSD in order to optimize treatment for patients with PTSD and comorbid substance use disorders.
COPE, a cognitive-behavioral treatment that represents a synthesis of theory-based and empirically validated treatments for PTSD (18) and substance use disorders (19), was designed in response to this need. The substance use treatment component is designed to help patients identify triggers (e.g., environmental, emotional) and high-risk situations for substance use and effectively manage cravings through a variety of techniques (e.g., stimulus control, decision delay, cognitive restructuring). Patients are taught a technique called “urge surfing,” which encourages them to sit with the craving and observe the natural rise and fall of the urge to use substances. Urge surfing is synergistic with exposure-based techniques and teaches patients that cravings, like anxiety, do not last forever and that patients are capable of “riding out the wave” of both anxiety and cravings. In addition, COPE teaches patients skills for managing anger, a symptom of PTSD and a frequent trigger for relapse in substance use disorders (13). The PTSD treatment component is designed to normalize common reactions to trauma and reduce PTSD symptoms through in vivo and imaginal exposure. In vivo exposure involves having patients repeatedly confront safe but anxiogenic situations that serve as trauma reminders and are avoided. Imaginal exposure involves having patients repeatedly revisit the memory of the traumatic event to help organize the memory, gain new perspective, decrease emotional reactivity to the memory, and enhance self-competence. Based on promising preliminary findings demonstrating the feasibility, safety, and efficacy of COPE among civilian samples (15, 20), we applied this treatment to a Marine veteran who had returned from combat service in Iraq.
We presented this case to stimulate discussion of improved models of treatment for PTSD and co-occurring substance use disorders. The case builds on an established body of knowledge demonstrating the efficacy of exposure-based treatments, as well as a burgeoning literature of promising results from integrative PTSD/substance use disorder interventions, and to our knowledge it is the first to report on the use of an exposure-based integrated treatment in a veteran of the conflicts in Afghanistan and Iraq. Investigations of combat veterans from previous eras demonstrate the chronicity and disability associated with PTSD and substance use disorders and highlight the urgent need for effective PTSD/substance use disorder interventions for veterans who served in these more recent conflicts.
Similar to results in studies of civilians, the application of trauma work did not result in exacerbated substance use. In particular, no increase in alcohol use was observed at the onset of in vivo or imaginal exposures. Although the patient continued to drink at a significantly reduced level during the course of therapy, substantial improvements in PTSD symptoms and overall functioning were achieved. This is important as it demonstrates that abstinence, although a goal that has been widely thought to maximize the benefits of treatment, is not essential before commencing trauma work and is not necessary for individuals to achieve substantial improvement in PTSD symptoms. Abstinence is, however, the safest goal, and it is possible that had the patient abstained from all substance use, further or more rapid improvements in PTSD symptoms would have been realized.
Conclusions
Evidenced-based interventions that effectively address PTSD and co-occurring substance use disorders are vitally needed in both civilian and Veterans Administration health care settings. This case report adds to accumulating data demonstrating the feasibility, safety, and efficacy of integrative PTSD/substance use disorder interventions employing exposure-based methods. The patient, a young, treatment-naive veteran with severe alcohol dependence and PTSD, exhibited significant improvements after completing a 12-session integrative intervention. Given these promising results, the treatment warrants further examination in order to optimize outcomes as well as durability of effects.
Acknowledgments
The authors thank Drs. Katherine Mills and Denise Hien for assistance with manual development and testing and Mr. Frank Beylotte and Ms. Amanda Federline for their assistance with data collection.
Footnote
Received Sept. 26, 2011; revision received Nov. 23, 2011; accepted Dec. 27, 2011.
References
1.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Dunbar, GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59:22–33
2.
Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a clinician-administered PTSD scale. J Trauma Stress 1990; 8:75–90
3.
Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA: Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther 1996; 34:669–673
4.
Beck AT, Steer RA, Brown GK: Beck Depression Inventory–II (BDI-II). San Antonio, Tex, Harcourt Assessment, 1996
5.
Sobell LC, Sobell MB: Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Edited by, Litten RZ, Allen JP. Totowa, NJ, Humana Press, 1992, pp 41–73
6.
Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59:12–19
7.
Gros DF, Simms LJ, Acierno R: Specificity of posttraumatic stress disorder symptoms: an investigation of comorbidity between posttraumatic stress disorder symptoms and depression in treatment-seeking veterans. J Nerv Ment Dis 2010; 198:885–890
8.
Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL: Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004; 351:13–22
9.
Milliken CS, Auchterlonie JL, Hoge CW: Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA 2007; 298:2141–2148
10.
Shea MT, Vujanovic AA, Mansielf AK, Sevin E, Liu F: Posttraumatic stress disorder symptoms and functional impairment among OEF and OIF National Guard and Reserve veterans. J Trauma Stress 2010; 23:100–107
11.
Booth-Kewley S, Larson GE, Highfill-McCoy RM, Garland CF, Gaskin TA: Psychological consequences of the wars in Iraq and Afghanistan. J Trauma Stress 2010; 23:69–77
12.
Bray RM, Pemberton MR, Lane ME, Hourani LL, Mattiko MJ, Babeu LA: Substance use and mental health trends among US active duty personnel: key findings from the 2008 DoD Health Behavior Survey. Mil Med 2010; 6:390–399
13.
Elbogen EB, Wagner HR, Fuller SR, Calhoun PS, Kinneer PM, Beckham JC: Correlates of anger and hostility in Iraq and Afghanistan war veterans. Am J Psychiatry 2010; 167:1051–1058
14.
Back SE: Toward an improved model of treating co-occurring PTSD and substance use disorders. Am J Psychiatry 2010; 167:11–13
15.
Brady KT, Dansky BS, Back SE, Foa AB, Carroll KM: Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. J Subst Abuse Treat 2001; 21:47–54
16.
Hien DA, Jiang H, Campbell ANC, Hu MC, Miele GM, Cohen LR, Brigham GS, Captick C, Kulaga A, Robinson J, Suarez-Morales L, Nunes EV: Do treatment improvements in PTSD severity affect substance use outcomes? a secondary analysis from a randomized clinical trial in NIDA'S clinical trials network. Am J Psychiatry 2010; 167:95–101
17.
Back SE, Brady KT, Sonne SC, Verduin ML: Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis 2006; 194:690–696
18.
Foa EB, Hembree EA, Rothbaum BO: Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences: Therapist Guide. New York, Oxford University Press, 2007
19.
Carroll KM: A Cognitive-Behavioral Approach: Treating Cocaine Addiction. Rockville, Md, National Institute on Drug Abuse, 1998
20.
Mills KL, Teesson M, Back SE, Baker A, Hopwood S, Brady K, Sannibale C: A randomized controlled trial of an integrated treatment for substance use and PTSD incorporating exposure therapy: preliminary findings, in Abstracts Presented at the 2008 Annual Meeting of the College on Problems of Drug Dependence (http://www.cpdd.vcu.edu/pp/Meetings/CPDD08AbstractBook2.pdf)
Information & Authors
Information
Published In
History
Received: 26 September 2011
Revision received: 23 November 2011
Accepted: 27 December 2011
Published online: 1 July 2012
Published in print: July 2012
Authors
Funding Information
Dr. Foa has received research support from or served as a speaker or consultant to Acetelion Pharmaceuticals, APA, Bristol-Myers Squibb, Cephalon, Ciba-Geigy, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Jazz Pharmaceuticals, Kali-Duphar, Pfizer, SmithKline Beecham, and Solvay. The other authors report no financial relationships with commercial interests.The authors acknowledge support from NIDA grant DA021228 (to Dr. Back).
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).